Growth Hormone (Somatropin) vs Oxandrolone (Anavar)

Mechanism

Recombinant human growth hormone (rhGH/somatropin) is a 191-amino acid protein identical to endogenous GH. It binds the GH receptor (GHR), a type I cytokine receptor, activating the JAK2-STAT5 signaling cascade that drives hepatic IGF-1 production — the primary mediator of GH's anabolic effects. GH directly stimulates lipolysis via hormone-sensitive lipase (HSL) activation and inhibits lipogenesis. It promotes chondrocyte proliferation, collagen synthesis, and linear bone growth. GH also enhances protein synthesis through mTOR pathway activation and improves nitrogen balance. Pulsatile secretion patterns are important — continuous GH exposure preferentially drives IGF-1, while pulsatile release favors direct lipolytic effects.

Standard Dosing

Research indicates 1-2 IU/day (0.33-0.67 mg/day) subcutaneously for anti-aging and body composition. Clinical GHD replacement: 0.2-0.6 mg/day titrated to IGF-1 levels.

Timing

Inject subcutaneously in the morning fasted (mimics physiological pulse) or before bed (mimics nocturnal secretion). Rotate injection sites (abdomen, thigh, deltoid). If using with insulin, separate GH injection by several hours. Fasted-state injection preferred for maximal lipolytic effect.

Cycle Duration

Long-term (6-12+ months) for body composition benefits. Clinical GHD replacement is indefinite. Minimum 3-6 months to assess efficacy.

Side Effects

• Fluid retention and edema (dose-dependent, typically resolves in 2-4 weeks)
• Carpal tunnel syndrome and joint pain
• Insulin resistance and elevated fasting glucose
• Headache
• Numbness and paresthesias
• Potential increased cancer risk with chronic supraphysiological IGF-1 levels
• Gynecomastia
• Acromegalic features with long-term excessive dosing (jaw growth, digit enlargement)

Contraindications

• Active malignancy (GH/IGF-1 promotes cell proliferation)
• Active proliferative or preproliferative diabetic retinopathy
• Acute critical illness (GH increased mortality in ICU patients)
• Active intracranial lesion or tumor
• Prader-Willi syndrome with severe obesity or respiratory impairment
• Closed epiphyses (for linear growth indication only)

Best Stacking Partners

Mechanism

Oxandrolone is a synthetic 17-alpha-alkylated dihydrotestosterone (DHT) derivative with a modified A-ring (replacement of C2 with an oxygen atom) that confers high anabolic-to-androgenic ratio (~10:1). It enhances protein synthesis by activating the androgen receptor while strongly binding sex hormone-binding globulin (SHBG), increasing free testosterone fraction. Oxandrolone directly stimulates phosphocreatine synthesis in skeletal muscle and has demonstrated anti-catabolic effects through cortisol receptor antagonism. In burn patients, it reverses catabolism by restoring the IGF-1/IGFBP-3 axis.

Standard Dosing

Research indicates 5-20 mg/day orally for therapeutic/recovery applications. Clinical burn protocols use 0.1 mg/kg twice daily.

Timing

Split into 2 doses (morning and evening) due to 9-hour half-life. Take with food to reduce GI discomfort.

Cycle Duration

Typical therapeutic cycles: 6-12 weeks. Clinical burn protocols have extended to 1 year+ with liver monitoring. Limit cycle length to minimize hepatic stress.

Side Effects

• Hepatotoxicity (dose and duration dependent — mild with therapeutic doses)
• Lipid profile disruption (significant HDL suppression, LDL elevation)
• Suppression of endogenous testosterone (dose dependent)
• Virilization in females at higher doses
• Headache
• Nausea
• Potential hair loss in genetically susceptible individuals

Contraindications

• Prostate cancer
• Breast cancer in males
• Hypercalcemia
• Severe hepatic impairment or active liver disease
• Nephrotic syndrome
• Pregnancy (Category X)

Best Stacking Partners